Topical hypochlorous acid (HOCl) blocks inflammatory gene expression and tumorigenic progression in UV-exposed SKH-1 high risk mouse skin

Jana Jandova\textsuperscript{a,b}, Jeremy Snell\textsuperscript{a,b}, Anh Hua\textsuperscript{a,b}, Sally Dickinson\textsuperscript{b}, Jocelyn Fimbres\textsuperscript{a,b}, Georg T. Wondrak\textsuperscript{a,b,*}

\textsuperscript{a} Department of Pharmacology and Toxicology, College of Pharmacy and UA Cancer Center, University of Arizona, Tucson, AZ, USA
\textsuperscript{b} UA Cancer Center, University of Arizona, Tucson, AZ, USA

\textbf{A R T I C L E I N F O}

\textbf{Keywords:}
Pathway-focused gene expression profiling
Hypochlorous acid
Skin cancer
Solar UV radiation
Inflammation
Oxidative stress

\textbf{A B S T R A C T}

Hypochlorous acid (HOCl) is the active oxidizing principle underlying drinking water disinfection, also delivered by numerous skin disinfectants and released by standard swimming pool chemicals used on a global scale, a topic of particular relevance in the context of the ongoing COVID-19 pandemic. However, the cutaneous consequences of human exposure to HOCl remain largely unknown, posing a major public health concern. Here, for the first time, we have profiled the HOCl-induced stress response in reconstructed human epidermis and SKH-1 hairless mouse skin. In addition, we have investigated the molecular consequences of solar simulated ultraviolet (UV) radiation and HOCl combinations, a procedure mimicking co-exposure experienced for example by recreational swimmers exposed to both HOCl (pool disinfectant) and UV (solar radiation). First, gene expression elicited by acute topical HOCl exposure was profiled in organotypic human reconstructed epidermis. Next, co-exposure studies (combining topical HOCl and UV) performed in SKH-1 hairless mouse skin revealed that the HOCl-induced cutaneous stress response blocks redox and inflammatory gene expression elicited by subsequent acute UV exposure (\textit{Nos2, Ptgs2, Hmox1, Srxn1}), a finding consistent with emerging clinical evidence in support of a therapeutic role of topical HOCl formulations for the suppression of inflammatory skin conditions (e.g. atopic dermatitis, psoriasis). Likewise, in AP-1 transgenic SKH-1 luciferase-reporter mice, topical HOCl suppressed UV-induced inflammatory signaling assessed by bioluminescent imaging and gene expression analysis. In the SKH-1 high-risk mouse model of UV-induced human keratinocytic skin cancer, topical HOCl blocked tumorigenic progression and inflammatory gene expression (\textit{Ptgs2, Il19, Tlr4}), confirmed by immunohistochemical analysis including 3-chloro-tyrosine-epitopes. These data illuminate the molecular consequences of HOCl-exposure in cutaneous organotypic and murine models assessing inflammatory gene expression and modulation of UV-induced carcinogenesis. If translatable to human skin these observations provide novel insights on molecular consequences of chlorination stress relevant to environmental exposure and therapeutic intervention.

1. Introduction

The small molecule electrophile hypochlorous acid (HOCl) is an important endogenous microbicidal component of the innate immune system derived from neutrophil myeloperoxidase (MPO) producing hypohalous acids. However, biological effects, toxicological impact, and potential therapeutic role of HOCl in skin (relevant to environmental toxicant exposure or topical disinfectant use) remain largely unexplored, particularly in the context of HOCl-mediated modulation of inflammatory gene expression and tumorigenesis.

HOCl, in equilibrium with its anionic form [hypochlorite (OCI\textsuperscript{-})] at physiological pH, may also induce tissue damage at sites of inflammation involving the oxidation and chlorination of biomolecules targeting peptides (e.g. glutathione), proteins, lipids, and nucleic acids [1–6]. Dysregulated HOCl production has been shown to contribute to a variety of human pathologies (such as atherosclerosis, rheumatoid arthritis, asthma, neuroinflammation, and cancer) [5–9]. Apart from endogenous HOCl produced in the context of physiological antimicrobial and inflammatory responses, human HOCl exposure can also occur through various exogenous environmental routes [10–14]. Indeed, based on the...
use of this powerful and versatile oxidant for freshwater preservation, operative on a global scale for both drinking water supply and public pool sanitation, human skin is subject to environmental HOCl exposure that occurs in the low ppm range [≤ 5 ppm (equating ≤ 100 μM) according to CDC and EPA guidelines] [12,14,15]. Health concerns associated with chlorinated drinking water and recreational exposure during swimming pool attendance have been raised before, particularly with a molecular focus on the role of HOCl and HOCl-derived organic chlorination byproducts. Inhalation, cutaneous exposure, and ingestion of irritant and carcinogenic disinfection byproducts (DBPs) have all been implicated in human pathogenesis (such as respiratory impairment and asthma exacerbation, allergic contact dermatitis, ocular/corneal irritation, and bladder cancer, respectively) [12,16]. Indeed, epidemiological evidence suggests that pool attendance correlates with increased asthma incidence in Olympic swimmers and pool workers, and consequences of HOCl exposure are now recognized as a potential public health concern [10,17–20].

Interestingly, in addition to endogenous and environmental sources, skin HOCl exposure also occurs through application of topical disinfectants employed worldwide as clinical and consumer products, a preventive use with particular relevance to the ongoing COVID-19 pandemic [21–23]. Remarkably, topical HOCl-based therapeutics optimized for sustained release are now serving as FDA-approved drugs for wound management, atopic dermatitis, pruritus, and psoriasis [24,25]. However, in spite of ubiquitous HOCl exposure of human tissues (i.e. cutaneous, pulmonary, and gastrointestinal epithelia), the specific molecular consequences of HOCl-associated electrostatic stress on structure and function of human skin remain largely unexplored.

Solar ultraviolet (UV) radiation is an important component of the skin exposure involved in photodamage and carcinogenesis including NMSC (nonmelanoma skin cancer), and potentiation of solar UV-induced cutaneous and systemic injury by co-exposure to other environmental toxicants and pollutants has attracted much attention impacting vulnerable populations worldwide [26–35]. Indeed, toxicants such as heavy metals (e.g. cadmium), metalloids (e.g. arsenic), and organic xenobiotics (e.g. benzopyrenes, dioxin) are established potentiators of solar UV damage [29–35]. HOCl, commonly referred to as ‘swimming pool chlorine’, is the most frequently-used halogen-based oxidizing pool disinfectant, and, according to CDC, there are 10.4 million residential and 309,000 public swimming pools and over 7.3 million hot tubs in the United States alone [11]. However, little prior research has addressed physiological and toxicological impact of HOCl co-exposure with solar UV as it occurs on a global scale in the context of recreational swimming pool use [10,12].

Here, for the first time, in an attempt to define the toxicological impact and potential therapeutic role of skin exposure to topical HOCl, we have profiled HOCl-induced cutaneous stress gene expression examined in reconstructed human epidermis and SKH-1 hairless mouse skin. In addition, using a focused gene array analysis approach, we have investigated the molecular consequences of acute skin HOCl exposure on redox and inflammatory gene expression elicited by subsequent solar simulated ultraviolet (UV) radiation, a procedure mimicking exposure experienced for example by recreational swimmers exposed to both HOCl (pool disinfectant) and UV (solar radiation). Finally, using an established photocarcinogenesis model (UV-exposed SKH-1 high-risk mouse skin) that mimics solar UV-induced carcinogenic initiation followed by tumorigenic progression, a situation relevant to the progression of human actinic keratosis to nonmelanoma skin cancer, the effects of topical HOCl administration on inflammatory gene expression and tumorigenesis were examined. Taken together, our data demonstrate that topical HOCl applied at environmentally relevant exposure levels blocks the UV-induced inflammatory gene expression response and suggest feasibility of using topical HOCl formulations for photochemoprevention of solar UV-induced NMSC.

2. Materials and methods

2.1. Chemicals

All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA).

2.2. Human skin cell culture

Human immortalized keratinocytes (HaCaT) were purchased from ATCC (Manassas, VA, USA) and maintained according to the manufacturer’s instructions. Briefly, keratinocytes were cultured in DMEM medium (Corning, Manassas, VA) supplemented with 10% bovine calf serum (HyClone™ Laboratories, Logan, UT). HOCl exposure was performed in PBS in order to minimize the impact of indirect chlorination reactions (e.g. HOCl-modification of serum proteins in medium that might confound cellular effects). Cells were maintained in a humidified incubator (37 °C, 5% CO₂ and 95% air) [36,37].

2.3. Cell viability analysis by flow cytometry

Cells were treated with HOCl (0–250 μM; in PBS, 1 h) followed by 23 h post-exposure culture in regular medium. Cell viability was then determined using flow cytometric analysis of annexinV (AV)-propidium iodide (PI) stained cells using an apoptosis detection kit (APO-AF, Sigma, St. Louis, MO) according to the manufacturer’s specifications as published before [38].

2.4. Human epidermal reconstructs

Before treatment, refrigerated epidermal reconstructs (EPI-200™, 9 mm diameter; MatTek, Corp., Ashland, MA) were equilibrated in fresh growth medium (0.9 ml; EPI-200-ASY media per well, 1 h), following our standard procedures for maintenance and treatment as published before [35,38–40]. Briefly, the stratum corneum of air exposed reconstructs was treated with HOCl [100 μM; in PBS; 30 min or 6 h exposure time, 37 °C; 5% CO₂]. Following exposure, epidermal reconstructs were processed for RNA extraction using the RNeasy Mini kit (Qiagen, Germantown, MD).

Comparative RT² Profiler™ gene expression array analysis: Total mRNA from cultured skin reconstructs or mouse skin was prepared using the RNeasy Mini kit (Qiagen) following our published standard procedures for maintenance and treatment as published before [38,41,42]. Reverse transcription was then performed using the RT² First Strand kit (Qiagen) from a total of 500 ng RNA. Human Oxidative Stress Plus (PAHS-065YA) and mouse Oxidative Stress (PAMM-065ZTA) RT² Profiler™ technology (Qiagen) assessing expression of 84 redox regulatory genes was used as published before [42]. Quantitative PCR was run using the following conditions: 95 °C (10 min), followed by 40 cycles at 95 °C (15 s) alternating with 60 °C (1 min) ( Applied Biosystems, Carlsbad, CA). Individual genes were normalized to a group of 5 housekeeping genes (human: ACTB, B2M, GAPDH, HRT1, RPLP0 and mouse: Actb, B2m, Gapdh, Gusb, Hsp90ab1) and quantified using the comparative ΔΔCt method (ABI Prism 7500 sequence detection system user guide).

2.5. Single RT-qPCR analysis

Total RNA from mouse skin was isolated using the Qiagen RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. Murine 20X primer/probe (Nos2 (Mm_00440502_m1), Pias2 (Mm_00478374_m1), Tmxp (Mm_01265659_g1), Tbf4 (Mm_00445272_m1), Il19 (Mm_01288324_m1), and Rps18 (Mm_02601777_g1)) were obtained from Fisher Scientific (Waltham, MA). cDNA synthesis was carried out by following cycling conditions using MJ Thermocycler PTC-200 (MJ Research, Watertown, MA): 25 °C for 10 min; 48 °C for 30 min and 95 °C for 5 min and subsequent amplification of target genes by following
conditions using ABI7500 Real-Time PCR System (Applied Biosystems, Foster City, CA); 95 °C for 10 min, 95 °C for 15 s and 60 °C for 1 min for a total of 40 cycles. Amplification of murine housekeeping gene \textit{Rps18} was used to examine the quality of cDNA. Non-template controls were included on each PCR plate. Expression levels of target genes were normalized to \textit{Rps18} control. Amplification plots were generated and the Ct values (cycle number at which fluorescence reaches threshold) recorded as published before [38,42].

2.6. Topical HOCl and UV exposure in the SKH-1 mouse model

For all experiments, six to eight-weeks old female SKH-1 Elite™ mice were purchased from Charles River Laboratories (Wilmington, MA) and housed and maintained in accordance with The University of Arizona Animal Care and Use Committee standards under an approved IACUC protocol (17–298).

2.7. Acute exposure murine model (UV and HOCl)

Mice were randomly allocated to one of the following treatment groups (five mice per group): group 1 (PBS carrier, 30 min, no UV); group 2 (100 μM HOCl, 30 min, no UV); group 3 (PBS carrier, 30 min, UV); group 4 (100 μM HOCl, 30 min, followed by UV). For topical exposure, hydrated gauze covered with Tegaderm™ (3 M Health Care, St. Paul, MN) containing either HOCl or PBS only was placed on the backs of mice (throughout the specified exposure time). Elizabethan collars (Braintree Scientific Inc., Braintree, MA) were used during this pre-treatment phase to avoid scratching-induced interference. Following 30 min pre-treatment, mice (groups 3 and 4) received UV exposure (UVA: 9.2 J/cm²; UVB: 480 mJ/cm²) using a solar simulator source [model 91293 (Oriel Corporation) equipped with a 1000W Xenon arc lamp] as published before [43]. Tissue samples for RNA and IHC were harvested 5 h 30 min after topical exposure (6 h total after initiation of experiment).

2.8. Epidermal AP-1 luciferase mouse model

SKH-1 mice expressing [12-O-tetradecanoylphorbol-13-acetate (TPA) response element] (TRE)-driven luciferase responsive to AP-1 transcriptional regulation were available at the UA Cancer Center and bred and maintained as published before [44,45]. Mice were separated into four groups as follows (three mice per group): ‘group 1’ [carrier, Vanicream™ (Pharmaceutical Specialties, Inc. Rochester, MN), no UV], ‘group 2’ (100 μM HOCl in Vanicream™, no UV), ‘group 3’ (Vanicream™, UV), ‘group 4’ (100 μM HOCl in Vanicream™, UV), Vanicream™ (with or without HOCl) was administered twice (dorsal skin; 24 h and 1 h) prior to dorsal UVB exposure (275 mJ/cm²) performed as published recently [44,45]. 24 h post UV exposure, quantitative bioluminescent imaging (Lago, Spectral Instruments Imaging, Tucson, AZ) was performed (using D-luciferin i.p. injection), and skin tissue was harvested for mRNA expression analysis.

2.9. High-risk (tumor-prone) mouse model

To generate the standard UV-exposed SKH-1 ‘high-risk’ (tumor-prone) mouse model, SKH-1 mice were subjected to a UVB exposure regimen as published before [46,47]. An irradiation panel of UVB-313 lamps (Q-LAB, Westlake, OH) was used, and the spectral output was quantified using a dosimeter from International Light Inc. (Newburyport, MA), model IL1700, with an SE240 detector for UVB (range 265–310 nm, peak 285 nm) at a distance of 365 mm from the source. This UV dose regimen delivers 190 μJ/cm² per UVB exposure (final dose; three times per week) [first six weeks of UV exposure: increasing dose regimen (week 1–2: 40%; week 3–4: 60%; week 5–6: 80% of final dose per exposure) to allow skin photo-adaptation]. At the end of the 112 d irradiation period, these mice are tumor free but have a high risk for developing papilloma/squamous cell carcinoma lesions over the next several weeks [46,47]. Two weeks after the end of the UV regimen pair-matched ‘high-risk’ mice (ten mice per group) received either topical HOCl (100 μM in 50 μl Vanicream™) or carrier only (Vanicream™), administered three times per week over a 24 d period, during which tumor development was monitored. At the end of the topical treatment period (38 d after last UV exposure), final tumor volume (cumulative tumor burden per animal) was determined.

2.10. Immunohistochemistry

After collection, tissues were fixed in 10% neutral buffered formalin (NBF) and processed for paraffin embedment. Sections from each tissue block were counterstained with hematoxylin/eosin (H&E) and analyzed for antigen detection: iNOS (NB300-605, Novus Biologicals), IL-19 (PAS-68455, Invitrogen), COX-2 (27308-1-AP, ProteinTech), 3-chloro-tyroline esteropos Rps18 (HP9002, HycultBiotech, Uden, Netherlands), and Ki67 (ab15580, Abcam) following our published procedures [41,42]. In brief, following deparaffinization and hydration, slides were subjected to heated antigen retrieval (citric, pH 6.0 or Tris-EDTA, pH 9.0). After overnight incubation in primary antibody, slides were incubated with biotinylated anti-mouse/anti-rabbit secondary antibody (RTU PK7200, Vector Laboratories, Burlingame, CA, USA) and a subsequent incubation with avidin/biotin streptavidin/horseradish peroxidase (Vectastain ABC, SK-4103, Vector Laboratories). Then, slides were developed with a diaminobenzidine/hydrogen peroxide mixture, counterstained with hematoxylin, dehydrated with graded alcohols and xylene, and mounted using a xylene based medium. Images were captured using an Olympus BX50 and Spot (Model 2.3.0) camera.

2.11. Statistical analysis

Unless stated differently, data sets were analyzed employing analysis of variance (ANOVA) with Tukey’s posthoc test using the GraphPad Prism 9.1.0 software (Prism Software Corp., Irvine, CA); in respective bar graphs (analyzing more than two groups), means without a common letter differ (p < 0.05) as published before [42]. For bar graphs comparing two groups only, statistical significance was calculated employing the Student’s two-tailed t-test. The level of statistical significance was marked as follows: *p < 0.05; **p < 0.01; ***p < 0.001. Experiments involved at least nine individual replicates per data point, except for gene expression array analysis performed with three independent biological replicates analyzed in triplicate format. Nonparametric data analysis of murine experimentation (average tumor burden) was performed using the Mann–Whitney test. Differences between groups were considered significant at p < 0.05.

3. Results

3.1. Array analysis reveals induction of redox stress response gene expression in human reconstructed epidermis (EpiDerm™) exposed to topical HOCl

First, in preparation of our skin reconstruct and murine explorations (Figs. 1–5), we established the dose response relationship of HOCl-induced cytotoxicity in cultured HaCaT human keratinocytes using annexin V-PI flow cytometry (Fig. 1a). To this end, cells were exposed to increasing concentrations of HOCl (up to 250 μM; in PBS, 1 h) followed by 23 h post-exposure culture in regular medium. Using this dose regimen, we observed that HOCl concentrations up to 100 μM were not associated with a significant impairment of viability. Next, human reconstructed epidermis was treated topically (100 μM HOCl in PBS, continuous exposure for 30 min or 6 h; maintained in 6 well format until time of harvest), followed by Oxidative Stress Plus RT² Profiler™ PCR Array analysis (HOCl-exposed relative to PBS control).

Upon prolonged exposure (6 h), five genes (out of a total of 84 genes
monitored), displayed statistically significant expression changes in response to HOCl treatment as depicted by (i) scatter plot (Fig. 1b), (ii) volcano plot [fold change over p-value (Fig. 1c)], and (iii) tabular summary of statistically significant gene expression changes [fold change ≥2; p value ≤0.05 (Fig. 1d)]. Genes displaying upregulated expression by at least 2-fold (6 h continuous exposure) were identified as TXNRD2 (encoding mitochondrial thioredoxin reductase 2; 69.2-fold), TPO (encoding thyroid peroxidase; 8.4-fold), MPO (encoding myeloperoxidase; 3.1-fold), APOE (encoding apolipoprotein E; 2.6-fold), and CCL5 [encoding chemokine C–C motif ligand 5 (RANTES); 2.5-fold]. Remarkably, two of these genes (TXNRD2, MPO) displayed HOCl-responsiveness with significant upregulation observable even after 30 min exposure only (Fig. 2d). At the same time, MTT-assay based assessment of tissue viability indicated that HOCl treatment (tested at the indicated dose and exposure time range) did not impair epidermal keratinocyte viability (data not shown).

Taken together, these data suggest that short term topical HOCl exposure at environmentally relevant concentrations induces a pronounced skin redox-related gene expression response that involves regulators of mitochondrial redox status (TXNRD2), skin barrier function (APOE), inflammation (CCL5), and reactive halogen species metabolism (TPO, MPO) [21,48–50].

3.2. Topical HOCl blocks inflammatory gene expression elicited by acute UV exposure in SKH-1 mouse skin

Next, the impact of acute topical HOCl exposure on cutaneous redox and inflammatory gene expression was assessed in SKH-1 mice serving as a relevant in vivo model. In addition, this experiment was designed to measure the effect of topical HOCl pre-exposure on subsequent solar UV-induced gene expression (Fig. 2). To this end, mouse skin was pretreated with ‘HOCl’ [100 μM in carrier (PBS), 30 min; ‘groups 2 and 4’] or ‘carrier only’ (‘groups 1 and 3’), followed by ‘UV exposure’ (‘groups 3 and 4’) or ‘mock UV’ treatment (‘groups 1 and 2’) (Fig. 2a).

First, responsiveness to HOCl treatment (‘group 2’) was confirmed by gene expression analysis (Oxidative Stress Plus RT² Profiler™ PCR Array) that indicated upregulated expression of redox regulatory genes including Gss (encoding glutathione synthetase; 45.8-fold), Sod3 (encoding superoxide dismutase 3; 2.5-fold), and Prdx5 (encoding peroxiredoxin 5; 2.1-fold). Remarkably, two of these genes (TXNRD2, MPO) displayed HOCl-responsiveness with significant upregulation observable even after 30 min exposure only (Fig. 2d). At the same time, MTT-assay based assessment of tissue viability indicated that HOCl treatment (tested at the indicated dose and exposure time range) did not impair epidermal keratinocyte viability (data not shown).

Next, UV-induced gene expression in SKH-1 mouse skin was profiled...
'group 3'; Fig. 2), characterized by pronounced upregulation of inflammatory genes including Nos2 [encoding inducible nitric oxide synthase 2 (iNOS); 486.6-fold], Ptgs2 [encoding prostaglandin-endoperoxide synthase 2 (COX-2); 3.5-fold], exclusively sensitive to isolated UV but not HOCl exposure. Moreover, UV-induced modulation of the antioxidant response including upregulation of Gss (33.3-fold), Hmox1 (encoding heme oxygenase 1; 26.2-fold), Srxn1 (encoding sulfiredoxin 1 homolog; 4.8-fold), Sod3 (2.3-fold), Gstk1 (2.3-fold), and Fth1 (2.1-fold) was detectable.

Next, the effect of HOCl pretreatment on UV-induced inflammatory gene expression ('group 4') was explored (Fig. 2). Strikingly, UV-induced upregulation of Nos2 and Ptgs2 expression was completely obliterated by cutaneous HOCl pretreatment, an observation supported by immunohistochemical staining for iNOS (Fig. 2e; left panel). In addition, the occurrence of HOCl-induced tissue chlorination stress was substantiated by the detection of 3-chloro-tyrosine-epitopes (Fig. 2e; right panel). A similar attenuation was observable with other stress response genes including Hmox1, Srxn1, and Sod3, but not with Gss (that displayed upregulated expression irrespective of HOCl pretreatment).

These differential expression data comparing transcriptional effects of single exposure (HOCl or UV) and combined exposure (HOCl + UV) are summarized by Venn diagram depiction (Fig. 2c). Likewise, the pronounced UV-induced downregulation of Noxa1 was strongly attenuated upon HOCl pretreatment.

Taken together, these observations indicate that topical HOCl treatment can suppress UV-induced inflammatory and redox stress response gene expression in an acute mouse skin exposure model.

3.3. Topical HOCl exposure blocks inflammatory gene expression elicited by acute UV exposure in AP-1 luciferase reporter SKH-1 mouse skin

Next, the impact of acute HOCl exposure on cutaneous inflammatory signaling was assessed using transgenic SKH-1 reporter mice expressing activator protein 1 (AP-1)-driven luciferase, a powerful genetic tool to monitor UV-induced AP-1 activation and its modulation by topical treatments impacting transcriptional activity of this major pro-inflammatory transcription factor [44,45]. In order to measure the effect of topical HOCl pre-exposure on subsequent solar UV-induced AP-1
signaling, mouse skin was pretreated with HOCl (100 μM in carrier) or ‘carrier only’, followed by UV exposure (UVB: 275 mJ/cm²) or ‘mock UV’ treatment (Fig. 3). As expected, UV-exposure caused pronounced AP-1 driven luciferase expression as evident from quantitative bioluminescent imaging, characterized by a more than 300-fold upregulation of photon emission over carrier control (Fig. 3a). In contrast, topical HOCl exposure did not induce AP-1 signaling, and, remarkably, HOCl pretreatment strongly attenuated subsequent UV-induced AP-1 activity by more than 50%. Consistent with this observation, UV-induced upregulation of cutaneous inflammatory gene expression (as assessed by single RT-qPCR) was either completely (Nos2) or partially downregulated [Ptgs2 (4.8-fold), Tlr4 (encoding toll-like receptor 4; 3.4-fold)].

Taken together, these observations indicate that topical HOCl treatment can suppress AP-1 driven inflammatory gene expression elicited by acute UV exposure as assessed in an engineered murine luciferase reporter system.

3.4. Topical HOCl blocks tumorigenic progression in UV-exposed SKH-1 high risk mouse skin

Next, we explored feasibility of using an HOCl topical regimen (delivered post-UV) for the suppression of cutaneous photocarcinogenesis as examined in an established murine model of UV-tumorigenesis (UV-exposed SKH-1 ‘high-risk’ mouse skin) (Figs. 4–5). Following a standard exposure regimen of tumorigenic UVB, tumor-prone SKH-1 ‘high risk’ mice were generated by subjecting mice to UV-exposure schedule (112 d duration) followed by a two week gap period, after which topical treatment was initiated, a standard regimen used widely for the identification of chemopreventive therapeutics suppressing photocarcinogenesis [47](Fig. 4a). At the beginning of day 127, ‘high risk’ mice received either compound in carrier (0.5% HOCl in Vanicream™) or carrier only (Vanicream™; three times per week; over a 24 d period). At the end of the treatment period (d 150), total tumor burden (i.e. tumor volume per mouse) was compared between treatment groups. A significant reduction in average tumor burden was observed in response to HOCl exposure, visible by ocular inspection (Fig. 4b) and substantiated by quantitative analysis (Fig. 4c,d). In HOCl-treated versus control SKH-1 ‘high risk’ mice, average tumor burden was suppressed by more than 75% [26.2 ± 19.2 (untreated) versus 6.2 ± 6.4 (treated)]. Taken together, these data suggest efficacy of topical HOCl to suppress UVB-induced tumorigenesis in a therapeutically relevant post-irradiation treatment regimen.

Next, high risk-skin specimens (‘group 1’ and ‘group 2’ (Fig. 4a)) were processed for comparative gene expression profiling and quantitative IHC imaging (Fig. 5). RT² Profiler™ PCR Array analysis revealed that in UV-induced high-risk SKH-1 mouse skin, expression of 20 genes was impacted by HOCl treatment (‘group 2’ compared to high-risk skin...
of the redox regulatory tumor suppressor gene HOCl treatment) revealed pronounced staining for IL-19, COX-2, and the analysis of tumor tissue originating from high-risk skin (not undergoing independent single RT-qPCR analysis (Fig. 5b and c) [42].

Consistent with expression data generated at the mRNA level, IHC analysis of tumor tissue originating from high-risk skin (not undergoing HOCl treatment) revealed pronounced staining for IL-19, COX-2, and the proliferation marker Ki67 consistent with expression array analysis (Fig. 5d). Furthermore, comparative IHC analysis of high-risk skin specimens [adjacent to tumor tissue; ‘group 1’ versus ‘group 2’] confirmed significant downregulation of IL-19 and COX-2 protein levels in response to post-UV topical HOCl treatment (Fig. 5e). Likewise, expression of the proliferation marker Ki67 (observable in the basal epidermis of high-risk mouse skin) was suppressed by topical HOCl treatment (more than seven-fold), and epidermal thickness, a key characteristic of chronic UV-induced hyperplasia, was diminished by more than 50% in response to HOCl exposure (Fig. 5e). Moreover, the occurrence of tissue chlorination resulting from topical HOCl exposure was substantiated by the detection of 3-chloro-tyrosine-epitopes (Fig. 5e).

Taken together, these data indicate that HOCl treatment can suppress skin photocarcinogenesis as assessed in a murine model of topical post-UV intervention at the phenotypic, transcriptomic, and protein expression levels.

4. Discussion

HOCl is a small molecule electrophile representing an important endogenous microbicidal component of the innate immune system, involved also in inflammatory pathologies and tissue remodeling relevant to wound healing, atherosclerosis, asthma, neurodegeneration, tumorigenesis, and chronological aging [5-9]. Remarkably, HOCl-induced oxidation also represents the mechanistic basis of freshwater preservation relevant to public drinking water safety and pool disinfection [10-14]. In addition, HOCl consumer products are used on a global scale for surface and skin disinfection targeting viruses, bacteria, and other microbes, a topic of contemporary relevance in the context of the unfolding COVID-19 pandemic [15,22,23].

Here we have investigated for the first time the effects of topical HOCl administration on solar UV-induced skin inflammatory gene expression and carcinogenesis in SKH-1 mouse skin. First, performing array analysis we observed that topical HOCl exposure induces a redox stress response gene expression in human reconstructed epidermis treated with carrier only (‘group 1’). Pronounced downregulation of gene expression in response to HOCl was observable impacting inflammatory factors (II19 (encoding interleukin 19; 94.3-fold), Ipo (encoding lactoperoxidase; 7.3-fold), Serpinb1b (encoding serine protease inhibitor 1b (7.1-fold), Ptg2 (6.2-fold), Duxo1 (encoding dual oxidase 1; 3.1-fold), and Tlr4 (2.9-fold)) (Fig. 5a and b), observations also confirmed by independent single RT-qPCR analysis of selected genes (Fig. 5c). At the same time, modulation of redox regulatory gene expression elicited by HOCl treatment of high-risk skin was observed, including upregulation ([≥3-fold]: Fmo2 (encoding flavin containing monooxygenase 2), Ucp3 (encoding mitochondrial uncoupling protein 3), Ncf1 (encoding neutrophil cytosol factor 1), Ncf2 (encoding neutrophil cytosol factor 2), Cyba (encoding cytochrome b-245 light chain), Aox1 (encoding aldehyde oxidase 1), and Fh1 (encoding ferritin heavy chain 1); downregulation ([≥3-fold]: Nqo1 (NAD(P)H dehydrogenase, quinone 1) and Gpx2 (encoding glutathione peroxidase 2) (Fig. 5a and b). In the context of treatment-induced suppression of skin tumorigenesis, it is also noteworthy that HOCl exposure was associated with upregulated expression of the redox regulatory tumor suppressor gene Txnip (encoding thioredoxin interacting protein; up to 4-fold), an observation confirmed by independent single RT-qPCR analysis (Fig. 5b and c) [42].
tumorigenic progression in UV-exposed SKH-1 high risk mouse skin.

Response might differ greatly as a function of exposure time, concentration of various dose regimens, since HOCl modulation of the skin UV-exposure model we observed that topical HOCl induces a redox gene expression profile and that inflammatory gene expression elicited by acute UV exposure was largely suppressed by HOCl pretreatment [52]. Moreover, the anti-inflammatory cutaneous effects of HOCl pretreatment were substantiated in an established AP-1 luciferase reporter SKH-1 mouse model (Fig. 3). Finally, we were able to demonstrate the chemopreventive efficacy of topical HOCl blocking porters SKH-1 mouse model (Fig. 3). (EpiDerm) (Fig. 1). Second, using SKH-1 mouse skin as a relevant exposure model we observed that topical HOCl induces a redox gene expression profile and that inflammatory gene expression elicited by acute UV exposure was largely suppressed by HOCl pretreatment (Fig. 2). Moreover, the anti-inflammatory cutaneous effects of HOCl pretreatment were substantiated in an established AP-1 luciferase reporter SKH-1 mouse model (Fig. 3). Finally, we were able to demonstrate the chemopreventive efficacy of topical HOCl blocking tumorigenic progression in UV-exposed SKH-1 high risk mouse skin (Figs. 4 and 5).

Obviously, more detailed follow up experiments are needed in order to comprehensively explore HOCl-induced cutaneous effects as a function of various dose regimens, since HOCl modulation of the skin UV-response might differ greatly as a function of exposure time, concentration, pH (carrier and skin), and pre-/co-/post-exposure application (51–53). For example, rapid HOCl/OCl− photodegradation by solar UBV involving photolytic cleavage (due to absorptivity around 295 nm) has been documented, an effect that is pH dependent, representing a confounding factor circumvented in our pilot studies employing an HOCl pre-exposure regimen performed under physiological pH conditions [52, 53].

Importantly, the mechanistic basis underlying HOCl-attenuation of the UV-induced cutaneous redox and inflammatory gene expression response remains to be explored. Hypochlorous acid-induced oxidation of biological targets including proteins, DNA, RNA, and lipids has been documented, and the related oxidation chemistry has been explored in much detail including (i) biochemical mechanisms of formation [such as MPO and related enzymes (TPO/LPO, EPO)], (ii) interaction with other reactive species (such as superoxide radical anion and NO), and (iii) target modification thought to underly microbialicidal activity during neutrophil respiratory burst and inflammation [1–6]. Among HOCl-related posttranslational modifications, chlorination of amino groups (causing chloramine formation), tyrosine chlorination [forming 3-chloro-tyrosine (3-Cl-Tyr)], and oxidation of cysteine residues has been observed in biological specimens contributing to various pathologies including inflammation, metabolic disease, sepsis, neurodegeneration, cancer, and aging [5, 6, 8, 9]. In addition, chlorination-derived protein adducts (including 3-Cl-Tyr) are useful biomarkers of chlorination stress in response to inflammatory dysregulation, caused by either endogenous sources (such as neutrophils) or exogenous exposure (due to environmental or therapeutic HOCl) [54, 55]. Indeed, topical exposure to HOCl as performed in our experiments, either following an acute exposure regimen (Fig. 2) or chronic exposure following solar UV-induced carcinogenesis (Fig. 5), was associated with significant introduction of 3-Cl-Tyr tissue epitopes staining the epidermal and portions of the sub-epidermal layers as detected by IHC analysis, consistent with the occurrence of chlorination stress as a result of the employed exposure regimens. However, molecular identity of specific chlorination targets and their mechanistic role in mediating HOCl-dependent biological effects in skin remains to be explored.

The specific mechanism underlying HOCl modulation of redox and inflammatory gene expression observed by us in human epidermal re-constructs and murine skin remains to be explored. For HOCl-sensitive redox-related genes [including reconstructed human epidermis: TXNRD2 etc. (Fig. 1); murine skin (acute exposure): Gis, Sod3, Prdx5 etc. (Fig. 2); murine skin (‘high risk’): Nqo1, Gpx2, Hmxox1, Sod3 etc. (Fig. 5)] an involvement of the redox-regulatory transcription factor Nr2f2 (modulated through HOCl-sensitive cysteine residues of its negative regulator Keap1) seems likely, a hypothesis to be substantiated by further experiments [56, 57].
Previous clinical research has demonstrated that HOCl-dependent cysteine oxidation causes IKK (IkB kinase) inactivation (through post-translational modification of Cys114 and 115) resulting in IkB stabilization and subsequent inhibition of NFkB nuclear translocation with suppression of inflammatory gene expression impacting established molecular mediators including the enzymes iNOS and COX-2 [8,9]. Indeed, cumulative evidence suggests that IKK inactivation represents the crucial mechanistic basis underlying HOCl-dependent therapeutic efficacy targeting psoriasis, a mechanism that has also been substantiated suppressing melanoma progression as a result of myeloid cell-derived HOCl [5,9]. Also, when examined in a mouse model of NFkB–driven acute radiation dermatitis, it has been reported that topical HOCl inhibited NFkB-dependent gene expression, decreased disease severity, and prevented skin ulceration. These specific IKK-directed effects might also underly the documented clinical efficacy of topical HOCl in the treatment of other inflammatory skin conditions including atopic dermatitis, pruritus, seborrheic dermatitis, acne vulgaris, diabetic ulcers, wound healing, and scars prevention [24,25]. Remarkably, a similar mechanism might be involved in HOCl antagonism of solar UV-induced AP-1 activation observed by us for the first time using a transgenic reporter mouse (Fig. 3). Indeed, the transcription factor AP-1, crucially involved in skin inflammatory dysregulation and photocarcinogenesis, has been shown to be sensitive to electrophile-dependent cysteine addition (c-Fos: Cys154; c-Jun: Cys272) suppressing skin photocarcinogenesis, a hypothesis to be tested by future experiments [44]. However, the specific mechanistic involvement of NFkB and AP-1 in the HOCl-induced attenuation of UV-induced skin inflammatory gene expression and carcinogenesis remains to be elucidated. Certainly, downregulation of major inflammatory mediators, including Nos2 and Ptgs2 might be attributable to HOCl-dependent antagonism targeting these two major pro-inflammatory regulators known to synergize regulating inflammatory gene expression, a scenario to be explored in more adequate detail [58,59].

It is also remarkable that in high-risk mouse skin, the inflammatory cytokine IL-1β displayed the most pronounced downregulation (at the mRNA and protein levels) in response to HOCl treatment (Fig. 5). IL-1β has now been identified as a crucial pathological driver in psoriasis, atopic dermatitis, and cutaneous T cell lymphoma in human patients suggesting that downregulation of IL-1β could be mechanistically involved in HOCl-dependent suppression of tumorigenesis [68–64]. Indeed, STAT3, the transcription factor mediating JAK/STAT signaling downstream of IL-19-dependent activation of the IL-20R1/IL-20R2 receptor heterodimer is an established tumorigenic factor in UV-induced squamous cell carcinoma [65]. Thus, HOCl-modulation of IL-1β (demonstrated here for the first time) might open up novel therapeutic avenues for cutaneous anti-inflammatory intervention. HOCl adduction of relevant molecular targets remains poorly understood, and apart from modulation of inflammatory pathways HOCl has also been shown to display cancer cell-directed activities including GRP78-mediated modulation of ER stress, autophagy, and proteotoxicity. Specifically, GRP78-directed Lys353 oxidation and other molecular pathways have been involved in HOCl-associated antimutagenic activity, a topic to be explored by future experiments in the context of HOCl-suppression of photocarcinogenesis [9,66,67]. Additionally, upregulation of the tumor suppressor gene Tmip observed by us in response to HOCl-exposure in the context of our UV-induced SKH-1 high risk mouse model might also be involved in the anti-tumorigenic activity of topical HOCl (Fig. 5b and c).

Taken together, these data illuminate for the first time the molecular consequences of HOCl-exposure in relevant cutaneous organotypic and murine models assessing inflammatory gene expression and modulation of UV-induced carcinogenesis. These observations if translatable to human skin provide novel insights on molecular consequences of chlorination stress relevant to environmental exposure and therapeutic intervention.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Supported in part by grants from the National Institutes of Health (1R01CA229418, 1R03CA230949, 2R12ES029579, 1PO1CA229112, ES007091, ES006694, and UA Cancer Center Support Grant CA023074). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

References

[1] J.M. Albritch, C.A. McCarthy, J.K. Hunt, Biological reactivity of hypochlorous acid: implications for microbial mechanisms of leukocyte myeloperoxidase, Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 210–214.
[2] C.L. Hawkins, M.J. Davies, Hypochlorite-induced damage to DNA, RNA, and polyamine: formation of chloramines and nitrogen-centered radicals, Chem. Res. Toxicol. 15 (2002) 84–92.
[3] C.L. Hawkins, D.I. Patterson, M.J. Davies, Hypochlorite-induced oxidation of amino acids, peptides and proteins, Amino Acids 25 (2003) 259–274.
[4] D.I. Patterson, C.L. Hawkins, M.J. Davies, Hypochlorous acid-mediated protein oxidation: how important are chloramine versus transfer reactions and protein tertiary structure? Biochemistry 46 (2007) 9853–9864.
[5] G. Bauer, HOCl and the control of oncogenesis, J. Inorg. Biochem. 179 (2018) 50–23.
[6] A. Urlik, L.I. Leichert, The effects of neoplastic-generated hypochlorous acid and other hypohalous acids on host pathogen, Cell. Mol. Life Sci. 78 (2021) 385–414.
[7] M. Costanzo, E. Di Salvo, E. Pace, E. Ventura-Spagnolo, M. Navarra, S. Gangemi, Chlorine stress in age-related diseases: a literature review, Immun. Aging 14 (2017) 21.
[8] T.H. Leung, L.F. Zhang, J. Wang, S. Ning, S.J. Knox, S.K. Kim, Topical hypochlorite ameliorates NF-kappaB-mediated skin diseases in mice, J. Clin. Invest. 123 (2013) 5361–5370.
[9] T.W. Liu, S.T. Gammon, P. Yang, D. Fuentes, D. Piwnica-Worms, Myeloid cell-derived HOCl is a paracrine effector that trans-inhibits IKK/NF-kappaB in melanoma cells and limits early tumor progression, Sci. Signal. 14 (207) (2021), eaax5971.
[10] World Health Organization, Guidelines for Safe Recreational Water Environments: VOLUME 2 SWIMMING POOLS and SIMILAR ENVIRONMENTS, 2006, ISBN 92 4 156680 8.
[11] T. H. I. C. P. A. C. (HICPAC), Guideline for Disinfection and Sterilization in Healthcare Facilities, Centers for Disease Control and prevention (CDC), 2008.
[12] S.D. Richardson, D.M. DeMarini, M. Kogevinas, P. Fernandez, E. Marco, C. Loosfelt-C, B. Balleste, D. Heederik, R. Melichar, A.B. McGuire, R. Marcos, L. Font-Ribera, J.O. Grimalt, C.M. Villanueva, What’s in the pool? A comprehensive identification of disinfection by-products and assessment of mutagenicity of chlorinated and brominated swimming pool water, Environ. Health Perspect. 118 (2010) 1523–1530.
[13] E.I. Prest, F. Hammes, M.C. van Loo, J.S. Vrouwenbeel, Biological stability of drinking water: controlling factors, methods, and challenges, Front. Microbiol. 7 (2016) 45.
[14] US Environmental Protection Agency (EPA) Ground water and drinking water. http://www.epa.gov/ground-water-and-drinking-water/emergency-disinfection-dri nkng-water (accessed: 4-29-2021).
[15] EPA (US Environmental Protection Agency); List N. Disinfectants for Use against SARS-CoV-2.
[16] A. Pardo, K. Nevo, D. Vignier, A. Lazarov, The effect of physical and chemical properties of swimming pool water and its close environment on the development of contact dermatitis in hydrotherapists, Am. J. Ind. Med. 50 (2007) 122–126.
[17] I. Helenius, T. Haahr, Allergy and asthma in elite summer sport athletes, J. Allergy Clin. Immunol. 106 (2000) 444–452.
[18] Y. Schuerer, A. Zutavern, I. Brockow, T. Schafer, U. Krammer, B. Schaaf, O. Herbahrth, A. von Berg, U.E. Wichmann, J. Heinrich, L. group, Health risks of early swimming pool attendance, Int. J. Hyg Environ. Health 211 (2008) 367–373.
[19] L. Font-Ribera, M. Kogevinas, J.P. Zock, M.J. Neuweninghuisen, D. Heederik, C. Villanueva, Swimming pool attendance and risk of asthma and allergic symptoms in children, Eur. Respir. J. 34 (2009) 1304–1310.
[20] A. Goma, R. de Lluis, J. Roca-Ferrer, J. Lafuent, C. Picado, Respiratory, ocular and skin health in recreational and competitive swimming: beneficial effect of a new method to reduce chlorine oxidant derivatives, Environ. Res. 152 (2017) 315–321.
[21] M.S. Block, B.G. Rowan, Hypochlorous acid: a review, J. Oral Maxillofac. Surg. 78 (2020) 1461–1466.
[22] G. Kampf, D. Todt, S. Pfendner, E. Steinmann, Persistence of coronaviruses on inanimate surfaces and their inactivation by biocidal agents, J. Hosp. Infect. 104 (2020) 246–251.
